Scarica l'app Stockscreener
13.58
2.51%
-0.35
Pre-mercato:
13.63
0.05
+0.37%
Amylyx Pharmaceuticals Inc Borsa (AMLX) Ultime notizie
Amylyx gets FDA fast track status for ALS treatment - MSN
Amylyx Stock: Why the Full Pipeline Story Matters - MarketBeat
Guggenheim Initiates Coverage of Amylyx Pharmaceuticals (AMLX) with Buy Recommendation - MSN
Amylyx Pharmaceuticals eyes phase 3 AVEXITIDE readout as 2027 launch comes into focus - MSN
AMLX Stock Price, Quote & Chart | AMYLYX PHARMACEUTICALS INC (NASDAQ:AMLX) - ChartMill
Amylyx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer FRATES JAMES M - Moomoo
Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 2026 Results and Pipeline Progress - Insider Monkey
AMLX News | AMYLYX PHARMACEUTICALS INC (NASDAQ:AMLX) - ChartMill
Amylyx Pharmaceuticals, Inc.Common Stock (NQ: AMLX - FinancialContent
Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Teva Pharmaceutical (TEVA) Reports Q1 Beat, Plans Amylyx Deal - Yahoo Finance
Number of shareholders of Amylyx Pharmaceuticals, Inc. – BOATS:AMLX - TradingView
Perceptive group holds 8.28M shares of Amylyx (AMLX) in Schedule 13G/A - Stock Titan
Amylyx publishes phase 2 Wolfram syndrome trial results - Investing.com
Amylyx publishes phase 2 Wolfram syndrome trial results By Investing.com - Investing.com Nigeria
Contributor: Fuel drug development, not Big Pharma's profits - AOL.com
Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation - Business Wire
B of A Securities Maintains Amylyx Pharmaceuticals (AMLX) Buy Recommendation - MSN
Amylyx (AMLX) Q1 2026 Earnings Transcript - AOL.com
Amylyx Pharmaceuticals Eyes Phase 3 AVEXITIDE Readout as 2027 Launch Comes Into Focus - inkl
Earnings call transcript: Amylyx Pharmaceuticals Q1 2026 earnings miss impacts stock By Investing.com - Investing.com South Africa
Earnings call transcript: Amylyx Pharmaceuticals Q1 2026 earnings miss impacts stock - Investing.com
Is It Too Late To Consider Amylyx Pharmaceuticals (AMLX) After A 220% One Year Surge? - simplywall.st
symbol__ Stock Quote Price and Forecast - CNN
TradingKey - TradingKey
Amylyx Readies Avexitide For PBH With Pivotal Trial And Valuation Gap - Sahm
Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), Annexon Biosciences (ANNX) and AMN Healthcare Services (AMN) - The Globe and Mail
Amylyx Pharmaceuticals (NASDAQ:AMLX) Cut to Sell at Wall Street Zen - MarketBeat
MSN Money - MSN
Amylyx Pharmaceuticals Charts Path to 2026 Trial Data - TipRanks
H.C. Wainwright Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $34 - Moomoo
12 Health Care Stocks Moving In Friday's Pre-Market SessionAbsci (NASDAQ:ABSI), Amylyx Pharmaceuticals - Benzinga
Amylyx Pharmaceuticals 1Q Loss/Shr 37c >AMLX - Moomoo
Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results - BioSpace
Buy Rating Reiterated on Amylyx as Avexitide Progress and Cash Runway Support Upside vs. Unchanged $24 Price Target - TipRanks
Earnings call transcript: Amylyx Pharmaceuticals Q1 2026 misses EPS forecast - Investing.com
Amylyx Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
AMLX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Amylyx Pharmaceuticals (NASDAQ:AMLX) Q1 Loss Slightly Wider Than Expected as All Eyes Turn to Q3 Avexitide Trial Data - ChartMill
Earnings Flash (AMLX) Amylyx Posts Q1 Loss $0.37 a Share, vs. FactSet Est of $0.35 Loss - marketscreener.com
1.92%
4.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):